Brainomix Selected for Future Fifty Scale-Up Programme

Brainomix, a global leader in AI-powered medical imaging, has been selected to join the Future Fifty, the UK's most prestigious scale-up programme. This recognition comes as the company continues to grow and innovate, making significant strides in the field of medical imaging technology.

The Future Fifty programme, delivered by Tech Nation and Founders Forum Group, supports the UK's most promising scaling companies. It has a track record of supporting 30% of all UK tech unicorns and 40% of the country's decacorns, including well-known companies like Revolut and Wise. The programme aims to provide these high-potential businesses with the connections, insights, and global exposure needed to scale their operations.

Brainomix joins the latest Future Fifty cohort alongside 24 other UK-based companies, spanning sectors such as AI, healthtech, biotech, fintech, energy, and advanced manufacturing. Collectively, these companies have raised £1.47 billion and employ more than 3,800 people.

The company's technologies are already being used to support clinicians in extracting greater insight from medical images to support more informed treatment decisions in stroke and lung diseases. Brainomix 360 Stroke and e-Lung, its flagship platforms, are now deployed across healthcare systems globally. This growing international footprint reflects the increasing adoption of Brainomix's AI-powered imaging solutions and the company's ambition to establish its technology as a global standard for more precise, data-driven treatment decisions.

Brainomix has secured £49 million in private and public funding and has achieved more than 30 FDA, CE, and other major regulatory clearances across its technology portfolio. The company has expanded its operations to more than 20 countries, further solidifying its position as a global leader in AI-powered medical imaging.

As Brainomix continues to scale, the company is investing in the further development of its imaging platforms, expanding its presence in key international markets, and building partnerships across healthcare and life sciences. The inclusion in Future Fifty provides an important platform to connect with fellow high-growth companies, industry leaders, and international networks as Brainomix enters its next phase of growth.